Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
28 11 2019
Historique:
received: 19 09 2017
accepted: 28 09 2017
pubmed: 6 2 2018
medline: 23 7 2020
entrez: 4 2 2018
Statut: ppublish

Résumé

The respiratory syncytial virus causes a considerable respiratory disease burden globally, most markedly in young infants, in low and middle income countries. A diverse product pipeline illustrates the recent intensification of research and development activities for vaccines and monoclonal antibodies against RSV. With the aim to ensure that product development activities are directed to address the public health needs, the World Health Organization has developed a research and development technical roadmap and articulated product characteristics preferences.

Identifiants

pubmed: 29395536
pii: S0264-410X(17)31364-6
doi: 10.1016/j.vaccine.2017.09.092
pii:
doi:

Substances chimiques

Antibodies, Monoclonal 0
Antibodies, Viral 0
Respiratory Syncytial Virus Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

7394-7395

Subventions

Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Medical Research Council
ID : MR/K012126/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R010161/1
Pays : United Kingdom

Informations de copyright

Copyright © 2017. Published by Elsevier Ltd.

Auteurs

Johan Vekemans (J)

World Health Organisation, Geneva, Switzerland. Electronic address: vekemansj@who.int.

Vasee Moorthy (V)

World Health Organisation, Geneva, Switzerland.

Brigitta Giersing (B)

World Health Organisation, Geneva, Switzerland.

Martin Friede (M)

World Health Organisation, Geneva, Switzerland.

Joachim Hombach (J)

World Health Organisation, Geneva, Switzerland.

Narendra Arora (N)

INCLEN Institute of Global Health, New Delhi, India.

Kayvon Modjarrad (K)

Walter Reed Army Institute of Research, Silver Spring, USA.

Peter G Smith (PG)

London School of Hygiene & Tropical Medicine, London, UK.

Ruth Karron (R)

John Hopkins Bloomberg School of Public Health, Baltimore, USA.

Barney Graham (B)

National Institute of Health, Bethesda, USA.

David C Kaslow (DC)

PATH, Seattle, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH